CUSIP: 05338F207
Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
5,550,979
-
Share change
-
+2,321
-
Total reported value
-
$27,984,339
-
Price per share
-
$5.04
-
Number of holders
-
26
-
Value change
-
+$12,113
-
Number of buys
-
14
-
Number of sells
-
6
Quarterly Holders Quick Answers
What is CUSIP 05338F207?
CUSIP 05338F207 identifies AVTX - AVALO THERAPEUTICS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2023
-
Previous quarter:
Q3 2022
Recent filing periods for CUSIP 05338F207:
Institutional Holders of AVALO THERAPEUTICS INC - COM NEW (AVTX) as of Q4 2022
As of 31 Dec 2022,
AVALO THERAPEUTICS INC - COM NEW (AVTX) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,550,979 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, Nantahala Capital Management, LLC, Point72 Asset Management, L.P., VANGUARD GROUP INC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, GOLDMAN SACHS GROUP INC, STATE STREET CORP, and SUSQUEHANNA INTERNATIONAL GROUP, LLP.
This page lists
26
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.